Anergy: the CLL cell limbo

Slides:

Advertisements

Similar presentations

An evolutionarily conserved program of B-cell development and activation in zebrafish by Dawne M. Page, Valerie Wittamer, Julien Y. Bertrand, Kanako L.

Advertisements

A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies by Jutta Deckert, Peter U. Park,

Evidence for anti-inflammatory activity of statins and PPARα activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes.

Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.

Investigating a New Methodology for the Detection of Low Frequency 17p Deleted Clones in Chronic Lymphocytic Leukaemia (CLL): Impact on Prognostic Outcome.

Lenalidomide augments actin remodeling and lowers NK- cell activation thresholds by Kathryn Lagrue, Alex Carisey, David J. Morgan, Rajesh Chopra, and Daniel.

The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.

Do HSCs divide asymmetrically?

VEGF therapy: risky business for established plaques?

by Dai Chida, Osamu Miura, Akihiko Yoshimura, and Atsushi Miyajima

by Nadine Martel, James Lee, and Philip S. Wells

Defects in DBA: more than meets the eye

Next-generation leukemia immunotherapy

In utero transplantation may soon be in delivery

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

by Zhenping Zhu Blood Volume 108(6): September 15, 2006

Glis: novel modulators of TCR signaling?

Tax fingerprint in adult T-cell leukemia

A cell by any other name by Narla Mohandas Blood

One giant leap for pediatric AMKL

How I treat elderly patients with myeloma

Mechanical Properties of Stored Red Blood Cells Using Optical Tweezers

How to Treat MDS without Stem Cell Transplantation

Skovseth et al. Endostatin dramatically inhibits endothelial cell migration, vascular morphogenesis, and perivascular cell recruitment in vivo. Blood.

Fusion genes in cord blood

An Unusual Cause of Abdominal Pain in Sickle Cell Disease

Functional neutrophils from human ES cells

Engineering regulatory T cells against factor VIII inhibitors

What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):

Fluorescent neutrophils throw the spotlight on inflammation

Mutation Analysis of the Rearranged Immunoglobulin Heavy Chain Genes of Marginal Zone Cell Lymphomas Indicates an Origin From Different Marginal Zone B.

Relationship of p53, bcl-2, and Tumor Proliferation to Clinical Drug Resistance in Non-Hodgkin's Lymphomas by Wyndham H. Wilson, Julie Teruya-Feldstein,

An actuarial GPS for hemophilic longevity

162. Stability of Polymer/Plasmid DNA Complexes In Vitro and In Vivo

Target recognition–induced NK-cell responses

by Sabah Sallah, and Jim Y. Wan

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

by Paolo Strati, Michael J. Keating, William G. Wierda, Xavier C

Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate by E.L.

Stage C or not stage C…? by Claire Dearden Blood

CXCR4 expression is associated with survival in familial chronic lymphocytic leukemia, but CD38 expression is not by Naoko Ishibe, Maher Albitar, Iman.

Ph+ ALL: drawing strength from a benign past

by Jon E. Arnason, Federico Campigotto, Donna Neuberg, and James B

HU for acute treatment of sickle VOC?

How I treat refractory CLL

Yang et al. SALL4 is a key regulator of survival and apoptosis in human leukemic cells. Blood. 2008;112(3):805–813. Blood Volume 114(14): October.

Chemokines and chemokine receptors: here, there, and everywhere

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation Anita D'Souza,

Docosahexaenoic Acid Alleviates Atopic Dermatitis in Mice by Generating T Regulatory Cells and M2 Macrophages Karyn A. Haitz, Niroshana Anandasabapathy

Figure 1 Evolution of blood cell counts during 18-month treatment and follow-up (A) Mean white blood cell count, (B) mean lymphocyte count, (C) mean eosinophil.

Haploidentical/Mismatched Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for T Cell Acute Lymphoblastic Leukemia Yu Wang,

What is quality in a transplant program?

Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin by Sarah L. Reeves, Hannah K. Jary, Jennifer.

Figure 1 Peripheral blood lymphocyte counts during dose titrationB-lymphocyte (CD19+; A) and total lymphocyte (CD45+; B) counts (cells/µL) in peripheral.

by Wendy Lim, Sara K. Vesely, and James N. George

Treatment versus Transplant for Challenging Hematologic Disorders

Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.

Sickle cells and sickle trait in thrombosis

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Rituximab immunotherapy: it’s getting personal

Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.

A binding relationship with thrombin

Hepatosplenic T-Cell Lymphoma: Clinicopathological Features and Treatment Outcomes: Report From The North American Peripheral T-Cell Lymphoma Consortium.

Patient Tregs express normal levels of suppression.

Initial treatment of CLL: integrating biology and functional status

by Victor A. Chow, Mazyar Shadman, and Ajay K. Gopal

A Review of First-Line Treatment for Small-cell Lung Cancer

Gene editing in hemophilia: a “CRISPR” choice?

Balancing bleeding in brain metastases

Presentation transcript:

Anergy: the CLL cell limbo by Federico Caligaris-Cappio Blood Volume 123(21):3214-3215 May 22, 2014 ©2014 by American Society of Hematology

Immunoglobulin M (IgM) secretion and cell morphology after 5 days of in vitro treatment of responsive (R) and non-responsive (NR) CLL samples with IL-21. Immunoglobulin M (IgM) secretion and cell morphology after 5 days of in vitro treatment of responsive (R) and non-responsive (NR) CLL samples with IL-21. See Figure 4A-B in the article by Duckworth et al that begins on page 3277. Federico Caligaris-Cappio Blood 2014;123:3214-3215 ©2014 by American Society of Hematology